OPINION ARTICLE

Deep brain stimulation in Gilles de la Tourette syndrome: killing several birds with one stone? [version 1; peer review: 3 approved]

Andreas Hartmann

1Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, CNRS UMR 7225, Paris, France
2Assistance Publique-Hôpitaux de Paris, Department of Neurology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
3French Reference Centre for Gilles de la Tourette Syndrome, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

Abstract

In patients with severe, treatment-refractory Gilles de la Tourette syndrome (GTS), deep brain stimulation (DBS) of various targets has been increasingly explored over the past 15 years. The multiplicity of surgical targets is intriguing and may be partly due to the complexity of GTS, specifically the various and frequent associated psychiatric comorbidities in this disorder. Thus, the target choice may not only be aimed at reducing tics but also comorbidities. While this approach is laudable, it also carries the risk to increase confounding factors in DBS trials and patient evaluation. Moreover, I question whether DBS should really be expected to alleviate multiple symptoms at a time. Rather, I argue that tic reduction should remain our primary objective in severe GTS patients and that this intervention may subsequently allow an improved psychotherapeutic and/or pharmacological treatment of comorbidities. Thus, I consider DBS in GTS not as a single solution for all our patients’ ailments but as a stepping stone to improved holistic care made possible by tic reduction.

Keywords

Tics, Tourette, deep brain stimulation (DBS), comorbidities

This article is included in the Tics collection.
Deep brain stimulation (DBS) has been used for over 15 years to treat severe forms of Gilles de la Tourette syndrome (GTS) refractory to pharmacological and, more recently, cognitive-behavioral therapies (CBT) (Schrock et al., 2015). Despite the relatively small numbers of patients operated so far, the number of surgical targets is impressive (Porta et al., 2013). The available double-blind trials favor the thalamus and the globus pallidus internus (both antero-medial and posteroventral parts) but the debate if these two are the best targets or if other targets need to be explored remains open (Servallo et al., 2016). As we have learnt from Parkinson disease, establishing just one or two consensual DBS targets is a long endeavor which requires time and a large number of patients (Lukins et al., 2014). Providing the latter will certainly be difficult in a comparatively rare disease like GTS.

Why so many potential targets in GTS? One of the main reasons appears to be the wish to diminish not only tics but also comorbidities (obsessive-compulsive disorder (OCD), impulsivity, attention deficit hyperactivity disorder (ADHD), anxiety, depression and others) which are present in almost 90% of patients meeting DSM criteria for GTS (Hirschtritt et al., 2015). Specifically, these patients fall into the category named « full-blown GTS » by Robertson (2015) and are also the most likely candidates to undergo surgery. Thus, a tailor-made, individualized approach might indeed make sense instead of including/randomizing patients into studies where a certain diagnostic uniformity is required or at least assumed.

I will argue that in an admittedly complex situation, Occam’s razor is the way to go forward. First, there is no GTS without tics. Challenging DSM-5 criteria is understandable but unrealistic (Robertson & Eapen, 2014). In clinical practice, however, even if DSM-5 criteria for GTS are met, we do of course establish the predominant symptoms in terms of impairment. Then, we chose the surgical target which we believe will be best suited to counter the main burden on the patient’s quality of life. This may mean that a patient with severe tics but even more severe OCD might actually be operated predominantly for the latter, targeting the subthalamic nucleus, for instance, which is not a usual target in GTS (Mallet et al., 2008). However, if tics are the main problem, then these should be treated first and foremost, which does not prevent us from evaluating comorbidities pre- and post-op by appropriate scales, as is done anyway in most current trials (Kefalopoulou et al., 2015). But we should be clear, for the time being, that obtaining a direct, surgically-induced effect on comorbidities will be the cherry on the cake, not something that can be systematically expected, at least based on our current knowledge of basal ganglia circuitry. That, for instance, was the rationale of the Paris group to implant electrodes into the limbic portions of the GPs, hoping to also reduce behavioral manifestations of GTS (Houeto et al., 2005; Welter et al., 2008). In a similar vein, I am doubtful of implanting multiple electrodes in multiple sites in the hope of alleviating surgically a host of neuropsychiatric symptoms; although I admit that in rare, very debilitating cases, this might be an option to consider.

My take is rather this: having severe, relentless and debilitating tics tend to cloud comorbidities. In case of successful DBS, other symptoms, rather than being co-treated by electrode implantation, may actually re-emerge. However, the patient is now free to pursue other forms of treatment for these symptoms, for instance psychostimulants for the treatment of ADHD if these previously aggravated tics. Even more importantly, psychotherapeutic approaches thus far impossible, notably cognitive behavioural therapy (CBT), can become feasible. An example from the OCD world concerns patients who underwent a 24 week CBT treatment programme after DBS of the nucleus accumbens (Mantione et al., 2014). Not only did CBT offer further symptom improvement: rather, as the authors note, all patients (n=16) had undergone previous CBT trials (between 1 and 9) which were not only unsuccessful but sometimes counterproductive because they majored anxiety and fear. DBS appeared to alleviate these symptoms and thereby made successful CBT possible. In a similar vein, CBT aimed at further tic reduction could be tried post-op where, pre-op, it was unfeasible. The same applies for psychotherapeutical approaches aiming to improve OCD, depression, anxiety and behavioral problems.

Therefore, and in conclusion, I suggest to view DBS in GTS as a window or a stepping stone to a more holistic treatment rather than a single solution for all our patients’ ailments.

Competing interests
No competing interests were disclosed.

Grant information
The author(s) declared that no grants were involved in supporting this work.

References


Open Peer Review

Current Peer Review Status: ✔ ✔ ✔

Version 1

Reviewer Report 28 September 2016

https://doi.org/10.5256/f1000research.10256.r16159

© 2016 Black K et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Kevin J. Black
Departments of Psychiatry, Neurology, Radiology, and Neuroscience, Washington University in St. Louis, St. Louis, MO, USA

Shan Siddiqi
Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA

This is an interesting and thoughtful take on the approach to DBS in GTS. Because GTS is a complex neuropsychiatric syndrome with a variety of different symptoms (or comorbidities), it may not be reasonable to assume that all of these symptoms will be alleviated by DBS; to the contrary, they may actually appear to be worsening because they were previously being masked by the tics. As the author suggests, it is impossible to make accurate assessments of a treatment's effect without first appropriately classifying the phenomenology of the illness and/or symptoms being targeted.

This article shows familiarity with the literature and clear writing, and is entirely appropriate for an Opinion Article.

We add a few comments, hopefully to further the discussion. The author argues well for focusing clinical trials for DBS in GTS on one problem at a time, namely tics. However, as he notes, the great majority of patients with GTS have clinical features other than tics. Gilbert and Buncher (2005)¹ include this observation of multiple symptoms as one of several features that complicate performing and interpreting clinical trials in GTS. Focusing DBS on the most problematic symptom in each patient may even prove to produce better results than focusing DBS on tics. But we have insufficient data to make such a judgment.

The issues identified by Prof. Hartmann highlight the critical importance of further clinical trials and of registering all DBS experience in GTS².

One trivial note: Substitute “exacerbated” for the word “majored” near the end of the article.

Shan H. Siddiqi
Kevin J. Black
References

Competing Interests: No competing interests were disclosed.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 23 September 2016
https://doi.org/10.5256/f1000research.10256.r16161

© 2016 Stern J. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Jeremy S. Stern
Department of Neurology, St George’s Hospital, St George’s Hospital Medical School, London, UK

Professor Hartmann's opinion article is a clear-thinking and original critique of the directions that DBS for GTS is taking. The field is perhaps expanding faster than uncertainties are being addressed, partly due to the heterogeneous nature of the condition and the possibility of several different surgical targets- variables that he surveys from an interesting perspective. I agree with him and Professor Cavanna that the practice of selecting modified surgical targets for tics based on comorbidites may lack a good evidence base, but the fundamental problem is establishing how to best to treat tics with DBS, including the prediction of beneficial effect for individual patients. The notion of DBS in GTS as an enabling therapy to allow conventional management strategies to be more successful needs further exploration and may prove an important principle.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 19 September 2016
https://doi.org/10.5256/f1000research.10256.r16164

© 2016 Cavanna A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
I found Andreas Hartmann’s considerations on the use of Deep Brain Stimulation (DBS) for patients with Tourette syndrome (TS) both clinically sensible and thought-provoking. The article is clearly written and the take-home message is convincingly argued: patients with TS who are candidates to DBS present by definition with a clinical picture characterised by highly severe and refractory tics. Rather than considering DBS as a panacea for the multifaceted neurobehavioural spectrum complicating patients’ presentations, the focus (and expectations) of DBS should remain anchored to tic alleviation. From a practical point of view, it has been observed that the DBS procedure can have wide-ranging effects, however the approach of a priori targeting multiple symptoms at the same time (“killing several birds with one stone”) can be prone to theoretical and clinical fallacies. Conversely, it would be interesting to test the sequential approach proposed by the author by systematically assessing changes in health-related quality of life in patients undergoing tic-focused neuromodulation, followed by specific therapeutic interventions for the residual behavioural co-morbidities.

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com